Kinfo
Ensysce Biosciences, Inc. Common Stock logo

Ensysce Biosciences, Inc. Common Stock

ENSCNASDAQHealthcare·US · USD
$0.40
-0.00 (-1.25%)
Prices as of October 2, 2026 · market closed

Price

Key statistics

Valuation
Market cap7.69M USD
Enterprise value6.88M USD
Trailing P/E0.02
Forward P/E-7.90
PEG ratio-0.00
Price / sales1.71
Price / book-4.61
Profitability
Gross margin0.00%
Operating margin-221.28%
Profit margin-280.48%
Return on assets-185.51%
Return on equity-1295.09%
Income (TTM)
Revenue4.50M USD
Gross profit-7.89M USD
EBITDA0.00 USD
Net income-12.62M USD
Diluted EPS-$2.56
Rev. growth (YoY)-15.10%
Balance sheet
Total cash676.70K USD
Total debt196.84K USD
Debt / equity-0.18
Current ratio0.70
Book value / share-$0.05
Cash flow (TTM)
Operating cash flow-8.86M USD
Levered free cash flow-4.15M USD
Shares & price
Shares outstanding15.37M
Float18.54M
Held by institutions4.65%
Beta0.99
50-day MA$0.40
200-day MA$0.49
52-week high$2.75
52-week low$0.23
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-13-0.50-0.20+60.00%2026-05-15-0.73-0.52+28.77%2026-03-30-1.26-0.75+40.48%2025-12-030.270.45+66.67%2025-11-14-0.93-1.29−38.71%
About Ensysce Biosciences, Inc. Common Stock

Ensysce Biosciences, Inc. Common Stock represents ownership in Ensysce Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing prescription therapies for severe pain and central nervous system conditions. The company’s current work centers on proprietary drug-delivery and abuse-deterrence platforms, including Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), which are designed to improve how certain medications are activated and to reduce the risks of misuse, abuse, and overdose. Its pipeline includes candidates for pain management, opioid protection, and attention deficit hyperactivity disorder, reflecting a focus on controlled pharmaceutical innovation rather than broad commercial medicines. Based in La Jolla, California, Ensysce Biosciences operates in the biotechnology and pharmaceuticals segment of the healthcare market, where it contributes to research-driven solutions aimed at safer treatment options for patients and clinicians.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. D. Lynn Kirkpatrick Ph.D.
Employees
8
Headquarters
La Jolla, CA, United States

Frequently asked questions about Ensysce Biosciences, Inc. Common Stock